Some of the most commonly discussed include: Wegovy, Zepbound, and Saxenda are approved for weight loss
Companies are racing to develop alternatives to injectable diabetes and weight loss drugs Injectable peptide drugs targeting the glucagon-like peptide 1 (GLP-1) receptor have had massive impact on approaches to treating diabetes and obesity, bringing huge revenue boosts to makers Novo Nordisk and Eli Lilly
2 The GLP-1 programme includes access to their app with GLP-1-specific features: meal tracking focused on protein and fibre targets (1g protein per kg of starting body weight), injection logging (tracking medication, dose, injection site, and side effects), on-demand strength training videos, and a library of GLP-1-specific recipes and articles
If DEXA scans are not accessible, waist circumference and body measurements provide useful proxies
For more on oral options, see our guide on oral semaglutide drops
Additionally, Semaglutide GLP-1 supports balanced blood sugar levels by enhancing insulin secretion in response to elevated glucose levels and suppressing glucagon release